# A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

> **NCT00833560** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag G.m.b.H** · enrollment: 401 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00833560
- **Lead sponsor:** Janssen-Cilag G.m.b.H
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833560, "A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00833560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*